Treatment
PD-1 Inhibitor + Chemotherapy clinical trials
We’re tracking 125 recruiting studies that include PD-1 Inhibitor + Chemotherapy, each written for real people, not researchers, below.
Recruiting studies
- NCT04908566RecruitingPhase 2
PD-1 immunotherapy plus chemotherapy before and after gastric surgery
This trial studies whether adding a PD-1 immune therapy to chemotherapy around the time of surgery can improve outcomes for people with locally advanced stomach or stomach–esophagus junction cancer. It aims to better control the cancer before and reduce the chance it comes back after surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT04997837RecruitingPhase 3
Adjuvant chemo with or without PD-1 for stomach cancer after surgery
This Phase 3 trial studies whether adding an immune medicine called PD-1 (given as an “inhibitor”) to standard chemotherapy and chemoradiation after stomach/GEJ cancer surgery can lower the risk of cancer coming back. You may qualify if you’ve had surgery removing the tumor and lymph nodes showed higher-risk disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05392413Recruiting
Predicting who benefits from PD-1 antibody for esophageal cancer
This study uses an “immune indicator model” to help predict how well a PD-1 antibody (a cancer-fighting immune drug) works when combined with chemotherapy for stage IV esophageal squamous cell cancer. If you qualify, you receive the treatment and the researchers also look for immune-related signs that may explain who benefits most.
GuangzhouAges 18–75 - NCT05563012RecruitingPhase 2
Short radiation plus chemo and PD-1 immunotherapy for stomach cancer
This Phase 2 trial tests whether giving a short course of radiation before surgery, along with chemotherapy and a PD-1 immunotherapy drug, can improve treatment outcomes for locally advanced stomach cancer. It may help shrink the tumor before surgery and strengthen the immune system’s attack on cancer.
Wuhan, HubeiAges 18–75 - NCT06006650RecruitingPhase 2
Neoadjuvant therapy for stage II-IVA esophageal cancer
This trial tests a treatment given before surgery for patients with a type of esophageal cancer called squamous cell carcinoma, stages II to IVA. The goal is to see if this approach can improve outcomes.
Xi'an, ShaanxiAges 18–75 - NCT06158919Recruiting
Immunotherapy Plus Targeted Therapy and Chemo for Stomach Cancer
This trial tests a combination of immunotherapy (PD-1 inhibitor), a targeted drug (fruquintinib), and chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that is HER2-negative. It aims to see if this combination can shrink tumors and help people live longer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07865793RecruitingPhase 2
Lattice radiation with immunotherapy for advanced tumors
This trial tests a new way to give radiation called lattice therapy together with immunotherapy drugs that help your immune system fight cancer. It is for people with advanced solid tumors that have grown or spread, with at least one large tumor that can be measured.
Shenzhen, GuangdongAges 18–70 - NCT07863141RecruitingPhase 2
Maintenance therapy after first-line chemoimmunotherapy for advanced esophageal cancer
This study compares two maintenance treatments after initial chemotherapy plus immunotherapy for advanced esophageal squamous cell carcinoma. The goal is to see if adding anlotinib, a targeted drug that blocks blood vessel growth to tumors, to a PD-1 inhibitor is more effective than the PD-1 inhibitor alone.
Guangzhou, GuangdongAges 18–75 - NCT06190782RecruitingPhase 3
Local therapy for limited metastatic esophageal cancer
This trial tests whether adding targeted radiation or other local treatments can help people with esophageal cancer that has spread to only a few spots (up to 4) after they've been treated with a PD-1 inhibitor. It aims to control the cancer better and improve outcomes.
ShanghaiAges 18 years+ - NCT06084897RecruitingPhase 2
Radiotherapy for metastatic esophageal cancer responding to immunotherapy
This trial tests whether adding radiotherapy can help people with metastatic esophageal cancer that has already responded well to initial treatment with immunotherapy and chemotherapy. It may offer a way to improve outcomes for those whose cancer has not progressed after 2-4 cycles of first-line treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06086457RecruitingPhase 3
Immunotherapy plus chemo with or without radiation for esophageal cancer
This trial tests whether adding radiation therapy to a standard treatment (immunotherapy plus chemotherapy) can help people with advanced esophageal cancer that has spread to up to two organs. The goal is to see if the combination improves outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07786766RecruitingPhase 2
Pemigatinib plus immunotherapy for FGFR2-positive bile duct cancer
This study tests a combination of two drugs—pemigatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—with or without chemotherapy, for people with advanced bile duct cancer that has an FGFR2 fusion or rearrangement. The goal is to see if this combination is more effective than standard treatment, and to find better ways to treat this type of cancer.
BeijingAges 18–80 - NCT06536959RecruitingPhase 2
VA plus PD-1 inhibitor for relapsed AML and high-risk MDS
This trial tests a combination of two drugs—a chemotherapy-like agent called VA and a PD-1 inhibitor (which helps your immune system fight cancer)—for people with AML or high-risk MDS that has not responded to or returned after initial treatment. The goal is to see if this combination can work better than standard treatments alone.
Beijing, Beijing MunicipalityAges 18–70 - NCT07781358RecruitingPhase 2
Testing a new drug combination for recurrent nasopharyngeal cancer
This trial tests a new drug combination for people whose nasopharyngeal cancer has come back in the same area or nearby lymph nodes. The goal is to see if this treatment can shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06632093Recruiting
Combination therapy for advanced liver cancer after standard treatment fails
This trial tests a triple combination of liver-directed chemotherapy (HAIC) plus immunotherapy (PD-1 inhibitor) and targeted therapy (Lenvatinib) for people with advanced liver cancer that has spread into the portal vein and who have already tried and failed standard treatments.
Shenyang, LiaoningAges 18–75 - NCT07669220RecruitingPhase 2
Short radiation, immunotherapy, and chemo for advanced rectal cancer
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
GuangzhouAges 18–75 - NCT07644286RecruitingPhase 2
Pirfenidone and immunotherapy with optional radiation for advanced colorectal cancer
This study tests a combination of three treatments—pirfenidone (an anti-scarring drug), a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), and sometimes radiation—for colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can slow or shrink your cancer.
Wuhan, HubeiAges 18–75 - NCT06702566Recruiting
Study of Ferritin in Immune-Related Side Effects
This study looks at how a blood marker called ferritin relates to side effects from immunotherapy or other cancer treatments. It may help doctors predict and manage those side effects better.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07555678RecruitingPhase 2
Chemotherapy, radiation, and immunotherapy for anal cancer
This study tests a combination of chemotherapy, radiation therapy, and an immunotherapy drug (anti-PD-1 antibody) for anal squamous cell cancer. The trial enrolls patients at different stages of disease to see if adding immunotherapy improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06752057Recruiting
Personalized vaccine plus immunotherapy and radiation for advanced lung cancer
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
Nanchang, JiangxiAges 18–70 - NCT06752044Recruiting
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized vaccine (made from your tumor's unique markers), a drug that boosts your immune system (PD-1 inhibitor), and targeted radiation for people with advanced lung cancer that has progressed after initial treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Nanchang, JiangxiAges 18–70 - NCT06751849RecruitingPhase 2
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized cancer vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation therapy for people with advanced non-small cell lung cancer that has gotten worse after at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow cancer growth.
Nanchang, JiangxiAges 18–70 - NCT06751901RecruitingPhase 2
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized peptide vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation for people with advanced non-small cell lung cancer whose disease has gotten worse after at least two standard treatments. It aims to see if this triple therapy can help control the cancer.
Nanchang, JiangxiAges 18–70 - NCT07519486RecruitingPhase 2
Nutrition support during cancer treatment before surgery
This trial tests whether intensive nutritional support helps patients with advanced esophageal cancer (a type of squamous cell carcinoma) respond better to treatment before surgery. The goal is to improve how well the cancer shrinks and prepare the body for a successful operation.
Chengdu, SichuanAges 18–80
What PD-1 Inhibitor + Chemotherapy is being studied for
Conditions with recruiting PD-1 Inhibitor + Chemotherapy studies.
Common questions
- Are there clinical trials studying PD-1 Inhibitor + Chemotherapy?
- Yes. Clin2 currently lists 125 recruiting studies that include PD-1 Inhibitor + Chemotherapy, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a PD-1 Inhibitor + Chemotherapy trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is PD-1 Inhibitor + Chemotherapy an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether PD-1 Inhibitor + Chemotherapy or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.